Pricing
  1. US-listed companies
  2. Regenicin, Inc.
  3. Raw

Regenicin, Inc.【RGIN】

Market cap
$15.35K
P/E ratio
SummaryFinancials
Back to summarized table
Sep 30,
2011		Sep 30,
2012		Sep 30,
2013		Sep 30,
2014		Sep 30,
2015		Sep 30,
2016		Sep 30,
2017		Sep 30,
2018		Sep 30,
2019		Sep 30,
2020		Sep 30,
2021
Net loss-3,665,582--2242,599-1,089,902973,937-559,058758,456559,591-877,102
Change in unrealized loss on securities---------3,950-1,72525
         Accrued interest on loans and notes payable-------17,499-47,050-34,713
              Accounts payable739,327221,124-380,251318,76833,02735,39970,766103,2945,015
              Accrued expenses  - other635,783955,9241420,151-401,020-271,28650,08024,956-69,798-143,745232,243
              Accrued salaries - officers-----334,250571,000581,000-581,000-581,001580,999
Net cash used in operating activities-1,774,552-1,058,929-685,142-211,845-1,996,685-693,272-311,705-133,721-126,862-123,199-24,107
         Proceeds of loans from officers-----229,147-107,49020,000121,108141,075123,75024,600
Net cash provided by financing activities567189,837-532,430-81,99044,791117,222124,975123,75024,600
NET INCREASE IN CASH----------493
       Cash paid for interest6,8752,0191,6644,453107,830--1,282453--
       Cash paid for taxes------7,986----